Smith Thomas B 4
4 · COLLEGIUM PHARMACEUTICAL, INC · Filed Feb 12, 2025
Insider Transaction Report
Form 4
Smith Thomas B
EVP and Chief Medical Officer
Transactions
- Tax Payment
Common Stock
2025-02-10$30.52/sh−1,498$45,719→ 92,141 total - Tax Payment
Common Stock
2025-02-10$30.52/sh−4,399$134,257→ 87,742 total - Award
Common Stock
2025-02-10+33,762→ 88,326 total - Award
Common Stock
2025-02-10+5,313→ 93,639 total
Footnotes (5)
- [F1]Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2026, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.
- [F2]Includes 373 and 375 shares acquired on July 19, 2024 and January 17, 2025, respectively, under the Issuer's employee stock purchase plan.
- [F3]Effective February 10, 2025, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 5,313 performance share units ("PSUs") granted in the Issuer's prior fiscal year.
- [F4]Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs.
- [F5]Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of RSUs.